Professor Woo-joo Kim “The effect of lowering the mortality rate cannot be announced…it is not enough for a game changer”
Celltrion “To lower the mortality rate, we need to stop severe transition”
(Seoul = Yonhap News) Reporter Gye Seung-Hyun = Amid rising expectations for Celltrion’s new coronavirus infection (Corona 19) antibody treatment, some pointed out that it is difficult to view this drug as a’game changer’.
Kim Woo-joo, a professor of infectious medicine at the ancient Guro Hospital, said on YouTube on the 14th, “It is not enough to say that it is a’game changer’ because the effect of lowering the mortality rate (Celltrion antibody treatment) has not been announced.”
Prof. Kim pointed out that the results of the Phase 2 clinical trial of Celltrion’s antibody treatment “Recyronaju” (ingredient name regdanvimab code name CT-P59), which were released the day before, did not contain any information on the study method, but only the results.
Professor Kim said, “In any study, the characteristics of the people who received treatment included in the study should be equal in both groups (placebo group and test group),” said Professor Kim. “Yesterday, only the results of the study were reported, so it may be overinterpreted than it is. “He said.
Professor Kim also added, “It is only possible to determine whether the result is meaningful only in the third phase of clinical trials, but it is difficult to accurately evaluate it from yesterday’s press release.”
(Seoul = Yonhap News) Celltrion’s self-developed novel coronavirus infection (Corona 19) antibody treatment “Recyronaju” (ingredient name legdanvimab code name CT-P59) shortens the recovery period of patients as a result of phase 2 clinical trials. , It has been shown to lower the incidence of severe cases. Celltrion released data on phase 2 clinical trials conducted on 327 patients with mild to moderate corona19 through a disclosure on the 13th. [연합뉴스 자료사진] [email protected]
“In order to reduce the mortality rate, it is necessary to recover as soon as possible without going to severe disease,” said Sang-jun Lee, senior vice president in charge of clinical trials at Celltrion. “This clinical trial was conducted for patients with mild and moderate illness. We are also considering one clinical trial.”
Senior Vice President Lee also said, “There is no problem with the balance between the placebo group and the test group,” he said. “It was not disclosed in detail due to the time limit for the presentation, but it will be announced through a paper and the Ministry of Food and Drug Safety is reviewing it in detail.”
Professor Kim also pointed out that it may be difficult to cope with mutant viruses due to the nature of monoclonal (monoclonal) antibody treatments.
Celltrion’s Rekironaju is a monoclonal antibody treatment made by selecting only antibodies that can neutralize the virus by binding to the spike protein on the surface of the virus in the blood of the plasma of a cure for Corona 19.
Professor Kim said, “Unfortunately, if a viral mutation occurs in the area where the antibody treatment is attached, the antibody does not adhere well, and if so, the efficacy will decrease.”
Professor Kim explained that vaccines and antiviral drugs are unlikely to be less effective in mutations.
Professor Kim said, “Vaccines are a mechanism by which our immune system makes countless antibodies by inoculating spike proteins as antigens, and antiviral agents block the function of protein (RdRP) that replicates viruses.”
Unauthorized reproduction-redistribution prohibited>
2021/01/14 15:14 sent